Physician profile
Mark E Romereim
NPI 1578621140
$41,453.93
in general payments reported to CMS, 2019-2025
17 companies · $13K in 2025
The $13K reported for 2025 was more than what 96% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $376 · 2020: $70.75 · 2021: $93.84 · 2022: $141 · 2023: $346 · 2024: $27K · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $18K · Honoraria: $14K · Travel and Lodging: $4,604 · Food and Beverage: $3,100 · Consulting Fee: $608 · Education: $160.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $18,000.00 |
| Honoraria | $14,300.00 |
| Travel and Lodging | $4,604.35 |
| Food and Beverage | $3,099.73 |
| Consulting Fee | $607.50 |
| Education | $160.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $23,887.88 | 2021-2024 | Qelbree, Qelbree |
| Axsome Therapeutics, INC. | $13,111.97 | 2022-2025 | Auvelity |
| Neuronetics, INC. | $2,463.83 | 2024 | Neurostar Tms Therapy System |
| Otsuka America Pharmaceutical, INC. | $750.04 | 2019-2024 | Rexulti |
| Janssen Pharmaceuticals, INC | $460.41 | 2019-2024 | Spravato |
| E.R. Squibb & Sons, L.L.C. | $176.58 | 2024-2025 | Cobenfy |
| Teva Pharmaceuticals USA, INC. | $127.02 | 2023-2024 | Uzedy |
| Abbvie INC. | $121.18 | 2023-2025 | Vraylar |
| Allergan, INC. | $116.74 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $72.34 | 2023 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $66.05 | 2023 | |
| Jazz Pharmaceuticals INC. | $22.79 | 2019 | |
| Ironshore Pharmaceuticals INC. | $18.55 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.45 | 2023 | Trintellix |
| Adlon Therapeutics L.P. | $14.43 | 2020 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $14.15 | 2020 | |
| Brainsway USA INC | $13.52 | 2024 | Brainsway Deep Tms System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Romereim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.